Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC dataOct 21Clinical readoutArcus Biosciences, Inc.casdatifanUpdated
Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilotAug 7Weekly roundup, 2 itemsArcus Biosciences, Inc.casdatifan
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Summit Therapeutics discloses going concern doubt alongside $380 million stock offeringJul 23FinancingivonescimabSummit Therapeutics